SCHEMBL712807

SCHEMBL712807

Cc1c[n+]([O-])c(C)c(C)c1OCC1COC(C)(C)OC1

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711097 0.89
SCHEMBL711059 0.77 APP (0.39) APP
SCHEMBL13528703 0.73
SCHEMBL712047 0.70 APP (0.38) APP
SCHEMBL712121 0.70 APP (0.38) APP
SCHEMBL9784645 0.70
Water SCHEMBL713364 0.69 APP (0.37) APP
SCHEMBL711464 0.68 AGXT (0.35) APP
SCHEMBL712557 0.67 AGXT (0.33) APP
SCHEMBL717265 0.67 CA2 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040564-B2 Stabilized composition EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-05-26 US disclosed
US-9040564-B2 Stabilized composition EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-05-26 US disclosed
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
US-20110009624-A9 BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-01-13 US disclosed
US-20110009624-A9 BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-01-13 US disclosed
EP-1870409-B1 BENZIMIDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-05-12 EP disclosed
EP-1870409-B1 BENZIMIDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-05-12 EP disclosed
US-20100022778-A1 PROCESS FOR PRODUCTION OF SULFINYLBENZIMIDAZOLE COMPOUNDS OR SALTS THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-01-28 US disclosed
US-20100022778-A1 PROCESS FOR PRODUCTION OF SULFINYLBENZIMIDAZOLE COMPOUNDS OR SALTS THEREOF EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-01-28 US disclosed
US-20080145421-A1 A layer of a benzamidazole-proton pump inhibitor and ethyl celluose is coated on an inert or basic material core material; an exterior layer of enteric polymer to prevent the dissolution of the drug in the stomach but in the intestines; storage stability; time-release agents; gastrointestinal disorders EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-06-19 US disclosed
WO-2008047849-A1 PROCESS FOR THE PRODUCTION OF 2- [ [4- T (2, 2-DIMETHYL-1, 3-DIOXAN-5-YL) METHOXY] PYRIDIN-2-YL] METHYLTHIO] -1H-BENZIMIDAZOLE EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-04-24 WO disclosed
WO-2008047849-A1 PROCESS FOR THE PRODUCTION OF 2- [ [4- T (2, 2-DIMETHYL-1, 3-DIOXAN-5-YL) METHOXY] PYRIDIN-2-YL] METHYLTHIO] -1H-BENZIMIDAZOLE EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-04-24 WO disclosed
EP-1875911-A1 STABILIZED COMPOSITION Eisai R&D Management Co., Ltd. (JP) 2008-01-09 EP disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080145421-A1 A layer of a benzamidazole-proton pump inhibitor and ethyl celluose is coated on an inert or basic material core material; an exterior layer of enteric polymer to prevent the dissolution of the drug in the stomach but in the intestines; storage stability; time-release agents; gastrointestinal disorders SI, CEL, PGA5 APP 4435/4885
US-20110009624-A9 BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION GIPR, HRH2, SI APP 4618/4885
US-20070010542-A1 Benzimidazole compound HRH2, GIPR, HRH4 APP 4883/4885
US-20070015782-A1 Benzimidazole compound HRH2, GIPR, HRH4 APP 4883/4885
US-20100022778-A1 PROCESS FOR PRODUCTION OF SULFINYLBENZIMIDAZOLE COMPOUNDS OR SALTS THEREOF SULT1E1, SULT1A1, SQOR APP 4572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.